

Chemoenzymatic Synthesis and Lectin Array Characterization of a Class of *N*-Glycan Clusters

Wei Huang,[†] Denong Wang,[‡] Masao Yamada,[§] and Lai-Xi Wang^{*,†}

Institute of Human Virology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201, Stanford Tumor Glycome Laboratory, Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, and GP Biosciences, Ltd., Yokohama 225-0012, Japan

Received September 16, 2009; E-mail: LWang@som.umaryland.edu

Abstract: *N*-Glycans are major components of many glycoproteins. These sugar moieties are frequently involved in important physiological and disease processes via their interactions with a variety of glycan-binding proteins (GBP). Clustering effect is an important feature in many glycan-lectin interactions. We describe in this paper a chemoenzymatic synthesis of novel *N*-glycan clusters using a tandem endoglycosidase-catalyzed transglycosylation. It was found that the internal β -1,2-linked GlcNAc moieties in the *N*-glycan core, once exposed in the nonreducing terminus, was able to serve as acceptors for transglycosylation catalyzed by Endo-A and EndoM-N175A. This efficient chemoenzymatic method allows a quick extension of the sugar chains to form a class of glycan clusters in which sugar residues are all connected by native glycosidic linkages found in natural *N*-glycans. In addition, a discriminative enzymatic reaction at the two GlcNAc residues could be fulfilled to afford novel hybrid clusters. Lectin microarray studies revealed unusual properties in glyco-epitope expression by this panel of structurally well-defined synthetic *N*-glycans. These new compounds are likely valuable for functional glycomics studies to unveil new functions of both glycans and carbohydrate-binding proteins.

Introduction

N-linked glycosylation is a predominant covalent modification of proteins in eukaryotes. It is well documented that *N*-glycans of glycoproteins are involved in many important biological events including protein folding, ER-associate protein degradation, cell differentiation, cell adhesion, host-pathogen interaction, cancer metastasis, and autoimmunity.¹ Glycoproteins are often characterized by their structural microheterogeneity in terms of the components of the attached glycans. It becomes clear that distinct *N*-glycans can confer significantly different effects on the structure and function of a given glycoprotein. This was exemplified by recent discoveries that the attachment of subtly different *N*-glycans at the conserved *N*-glycosylation site of the Fc domain could result in dramatically different impacts on the ADCC function of monoclonal antibodies and on the anti-inflammatory activity of intravenous immunoglobulin (IVIG).² On the other hand, not only does the fine structure of the glycans

provide the basis for molecular recognition, but the way of their presentation, e.g., the monovalent vs multivalent format, is also of paramount importance in governing the specificity and strength in carbohydrate–protein interactions.³ Recent advances in glycan and glycan-binding protein microarray technology have offered exciting new opportunities to unveil the mysteries of glycans in various cellular processes and disease states.⁴ Nevertheless, functional glycomics studies are still limited by the availability of structurally well-defined *N*-glycans and related glycoconjugates, which are difficult to obtain in homogeneous forms from natural source.⁵

We and others have previously demonstrated that a class of endo- β -*N*-acetylglucosaminidases (ENGases), including the

[†] University of Maryland School of Medicine.

[‡] Stanford University School of Medicine.


[§] GP Biosciences, Ltd.

- (1) (a) Varki, A. *Glycobiology* **1993**, *3*, 97–130. Dwek, R. A. *Chem. Rev.* **1996**, *96*, 683–720. (b) Helenius, A.; Aebi, M. *Science* **2001**, *291*, 2364–2369. (c) Haltiwanger, R. S.; Lowe, J. B. *Annu. Rev. Biochem.* **2004**, *73*, 491–537. (d) Dube, D. H.; Bertozzi, C. R. *Nat. Rev. Drug Discov.* **2005**, *4*, 477–488. (e) Arnold, J. N.; Wormald, M. R.; Sim, R. B.; Rudd, P. M.; Dwek, R. A. *Annu. Rev. Immunol.* **2007**, *25*, 21–50. (f) Gamblin, D. P.; Scanlan, E. M.; Davis, B. G. *Chem. Rev.* **2009**, *109*, 131–163.
- (2) (a) Jefferis, R. *Biotechnol. Prog.* **2005**, *21*, 11–16. (b) Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V. *Science* **2006**, *313*, 670–673. (c) Anthony, R. M.; Nimmerjahn, F.; Ashline, D. J.; Reinhold, V. N.; Paulson, J. C.; Ravetch, J. V. *Science* **2008**, *320*, 373–376.

- (3) (a) Lee, R. T.; Lee, Y. C. *Glycoconjugate J.* **2000**, *17*, 543–551. (b) Lundquist, J. J.; Toone, E. J. *Chem. Rev.* **2002**, *102*, 555–578. (c) Brewer, C. F.; Miceli, M. C.; Baum, L. G. *Curr. Opin. Struct. Biol.* **2002**, *12*, 616–623.
- (4) (a) Blixt, O.; et al. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 17033–17038. (b) Feizi, T.; Chai, W. *Nat. Rev. Mol. Cell Biol.* **2004**, *5*, 582–588. (c) Xia, B.; Kowar, Z. S.; Ju, T.; Alvarez, R. A.; Sachdev, G. P.; Cummings, R. D. *Nat. Methods* **2005**, *2*, 845–850. (d) Oyeleran, O.; Gildersleeve, J. C. *Expert Rev. Vaccines* **2007**, *6*, 957–969. (e) Pilobello, K. T.; Mahal, L. K. *Curr. Opin. Chem. Biol.* **2007**, *11*, 300–305. (f) Hirabayashi, J. *J. Biochem.* **2008**, *144*, 139–147. (g) Zhao, J.; Patwa, T. H.; Lubman, D. M.; Simeone, D. M. *Curr. Opin. Mol. Ther.* **2008**, *10*, 602–610. (h) Liang, P. H.; Wu, C. Y.; Greenberg, W. A.; Wong, C. H. *Curr. Opin. Chem. Biol.* **2008**, *12*, 86–92. (i) Hsu, K. L.; Mahal, L. K. *Curr. Opin. Chem. Biol.* **2009**, *13*, 427–432. (j) Oyeleran, O.; Gildersleeve, J. C. *Curr. Opin. Chem. Biol.* **2009**, *13*, 406–413. (k) Song, X.; Xia, B.; Stowell, S. R.; Lasanajak, Y.; Smith, D. F.; Cummings, R. D. *Chem. Biol.* **2009**, *16*, 36–47.
- (5) (a) Raman, R.; Raguram, S.; Venkataraman, G.; Paulson, J. C.; Sasisekharan, R. *Nat. Methods* **2005**, *2*, 817–824. (b) Paulson, J. C.; Blixt, O.; Collins, B. E. *Nat. Chem. Biol.* **2006**, *2*, 238–248.

Endo-A from *Arthrobacter protophormiae* and the Endo-M from *Mucor hiemali*, were able to transfer an oligosaccharide *en bloc* from either natural *N*-glycans or synthetic sugar oxazolines to a GlcNAc-containing moiety to form a new β -1,4-glycosidic linkage in a regio- and stereospecific manner, leading to the synthesis of complex oligosaccharides, *N*-glycopeptides and *N*-glycoproteins.⁶ Endo-A is specific for high-mannose or hybrid-type *N*-glycans and has been applied for the synthesis of high-mannose-type oligosaccharides and *N*-glycopeptides,⁷ whereas Endo-M is able to work on three major types (high-mannose, hybrid, and complex type) of *N*-glycans and has been particularly useful for synthesizing complex type *N*-glycopeptides.⁸ In particular, the recent findings that synthetic oligosaccharide oxazolines (the mimics of the oxazolinium ion intermediate of the enzymatic reaction) could be used for Endo-A-catalyzed transglycosylation have significantly expanded the scope of the chemoenzymatic method for glycopeptide and glycoprotein synthesis.^{9–11} It was found that the highly activated sugar oxazolines corresponding to the truncated or modified *N*-glycans could serve as substrates for the Endo-A-catalyzed transglycosylation, but the ground-state products formed were

Scheme 1



refractory to enzymatic hydrolysis due to the slight structural modification. Moreover, the discovery of several ENGase-based glycosynthases, including EndoM-N175A; EndoA-N171A, and EndoA-E173Q that could promote transglycosylation with sugar oxazolines of natural *N*-glycans but lack the ability to hydrolyze the product, has enabled the synthesis of homogeneous glycoproteins carrying full-size natural *N*-glycans.^{12–14} Subsequent studies indicate that Endo-A and Endo-M could accommodate diverse structures in the aglycon portions of GlcNAc- or Glc-tagged acceptors for transglycosylation, permitting the introduction of *N*-glycans into a wide range of natural products, unnatural peptides, and even polysaccharides.^{15,16} The relaxed substrate specificity of Endo-A and Endo-M, together with the powerful transglycosylation potential of the glycosynthase mutants, prompted us to examine the possibility to glue multiple *N*-glycans to the complex-type GlcNAc2Man3GlcNAc2-Asn core through tandem enzymatic transglycosylation. We report in this contribution the chemoenzymatic synthesis of a class of novel *N*-glycan clusters containing multiple *N*-glycan cores, in which all monosaccharide residues are connected via defined native glycosidic bonds found in natural *N*-glycans. Lectin microarray analysis of the synthetic *N*-glycan clusters has revealed unusual lectin–carbohydrate recognition patterns that were not observed before.


Results and Discussions

Enzymatic Transglycosylation onto the β -1,2-Linked GlcNAc Residues in the Asn-Linked GlcNAc2Man3GlcNAc2 Core. Construction of an array of *N*-glycan clusters started with the preparation of a biotinylated biantennary complex type *N*-glycan (Scheme 1). Coupling of glycosylamine **2** and an activated biotin tag (**3**) gave the GlcNAc-LC-biotin (**4**), which was then used as an acceptor for enzymatic transglycosylation. We have previously reported the synthesis of an asialoglycan oxazoline

- (6) (a) Yamamoto, K. *J. Biosci. Bioeng.* **2001**, *92*, 493–501. (b) Wang, L. X. *Carbohydr. Res.* **2008**, *343*, 1509–1522.
- (7) (a) Takegawa, K.; Yamaguchi, S.; Kondo, A.; Kato, I.; Iwahara, S. *Biochem. Int.* **1991**, *25*, 829–835. (b) Takegawa, K.; Yamaguchi, S.; Kondo, A.; Iwamoto, H.; Nakoshi, M.; Kato, I.; Iwahara, S. *Biochem. Int.* **1991**, *24*, 849–855. (c) Fan, J. Q.; Takegawa, K.; Iwahara, S.; Kondo, A.; Kato, I.; Abeygunawardana, C.; Lee, Y. C. *J. Biol. Chem.* **1995**, *270*, 17723–17729. (d) Takegawa, K.; Tabuchi, M.; Yamaguchi, S.; Kondo, A.; Kato, I.; Iwahara, S. *J. Biol. Chem.* **1995**, *270*, 3094–3099. (e) Wang, L. X.; Fan, J. Q.; Lee, Y. C. *Tetrahedron Lett.* **1996**, *37*, 1975–1978. (f) Wang, L. X.; Tang, M.; Suzuki, T.; Kitajima, K.; Inoue, Y.; Inoue, S.; Fan, J. Q.; Lee, Y. C. *J. Am. Chem. Soc.* **1997**, *119*, 11137–11146. (g) Deras, I. L.; Takegawa, K.; Kondo, A.; Kato, I.; Lee, Y. C. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1763–1766. (h) Fujita, K.; Takegawa, K. *Biochem. Biophys. Res. Commun.* **2001**, *282*, 678–682. (i) Fujita, K.; Miyamura, T.; Sano, M.; Kato, I.; Takegawa, K. *J. Biosci. Bioeng.* **2002**, *93*, 614–617. (j) Singh, S.; Ni, J.; Wang, L. X. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 327–330. (k) Li, H.; Singh, S.; Zeng, Y.; Song, H.; Wang, L. X. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 895–898. (l) Wang, L. X.; Song, H.; Liu, S.; Lu, H.; Jiang, S.; Ni, J.; Li, H. *ChemBioChem* **2005**, *6*, 1068–1074.
- (8) (a) Yamamoto, K.; Kadowaki, S.; Watanabe, J.; Kumagai, H. *Biochem. Biophys. Res. Commun.* **1994**, *203*, 244–252. (b) Haneda, K.; Inazu, T.; Yamamoto, K.; Kumagai, H.; Nakahara, Y.; Kobata, A. *Carbohydr. Res.* **1996**, *292*, 61–70. (c) Haneda, K.; Inazu, T.; Mizuno, M.; Iguchi, R.; Yamamoto, K.; Kumagai, H.; Aimoto, S.; Suzuki, H.; Noda, T. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1303–1306. (d) Mizuno, M.; Haneda, K.; Iguchi, R.; Muramoto, I.; Kawakami, T.; Aimoto, S.; Yamamoto, K.; Inazu, T. *J. Am. Chem. Soc.* **1999**, *121*, 284–290. (e) Mori, T.; Sekine, Y.; Yamamoto, K.; Okahata, Y. *Chem. Commun. (Cambodia)* **2004**, 2692–2693. (f) Yamanai, T.; Yoshida, N.; Oda, Y.; Akaike, E.; Tsutsumida, M.; Kobayashi, N.; Osumi, K.; Yamamoto, K.; Fujita, K.; Takahashi, K.; Hattori, K. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1009–1013. (g) Fujita, K.; Yamamoto, K. *Biochim. Biophys. Acta* **2006**, *1760*, 1631–1635. (h) Makimura, Y.; Watanabe, S.; Suzuki, T.; Suzuki, Y.; Ishida, H.; Kiso, M.; Katayama, T.; Kumagai, H.; Yamamoto, K. *Carbohydr. Res.* **2006**, *341*, 1803–1808. (i) Haneda, K.; Takeuchi, M.; Tagashira, M.; Inazu, T.; Toma, K.; Isogai, Y.; Hori, M.; Kobayashi, K.; Takegawa, K.; Yamamoto, K. *Carbohydr. Res.* **2006**, *341*, 181–190.
- (9) (a) Fujita, M.; Shoda, S.; Haneda, K.; Inazu, T.; Takegawa, K.; Yamamoto, K. *Biochim. Biophys. Acta* **2001**, *1528*, 9–14. (b) Li, H.; Li, B.; Song, H.; Breydo, L.; Baskakov, I. V.; Wang, L. X. *J. Org. Chem.* **2005**, *70*, 9990–9996. (c) Wei, Y.; Li, C.; Huang, W.; Li, B.; Strome, S.; Wang, L. X. *Biochemistry* **2008**, *47*, 10294–10304. (d) Rising, T. W.; Claridge, T. D.; Davies, N.; Gamblin, D. P.; Moir, J. W.; Fairbanks, A. J. *Carbohydr. Res.* **2006**, *341*, 1574–1596. (e) Rising, T. W.; Claridge, T. D.; Moir, J. W.; Fairbanks, A. J. *ChemBioChem* **2006**, *7*, 1177–1180. (f) Rising, T. W.; Heidecke, C. D.; Moir, J. W.; Ling, Z.; Fairbanks, A. J. *Chem.—Eur. J.* **2008**, *14*, 6444–6464.
- (10) Li, B.; Zeng, Y.; Hauser, S.; Song, H.; Wang, L. X. *J. Am. Chem. Soc.* **2005**, *127*, 9692–9693.

- (11) (a) Li, B.; Song, H.; Hauser, S.; Wang, L. X. *Org. Lett.* **2006**, *8*, 3081–3084. (b) Zeng, Y.; Wang, J.; Li, B.; Hauser, S.; Li, H.; Wang, L. X. *Chem.—Eur. J.* **2006**, *12*, 3355–3364. (c) Ochiai, H.; Huang, W.; Wang, L. X. *J. Am. Chem. Soc.* **2008**, *130*, 13790–13803.
- (12) Umekawa, M.; Huang, W.; Li, B.; Fujita, K.; Ashida, H.; Wang, L. X.; Yamamoto, K. *J. Biol. Chem.* **2008**, *283*, 4469–4479.
- (13) Huang, W.; Li, C.; Li, B.; Umekawa, M.; Yamamoto, K.; Zhang, X.; Wang, L. X. *J. Am. Chem. Soc.* **2009**, *131*, 2214–2223.
- (14) Heidecke, C. D.; Ling, Z.; Bruce, N. C.; Moir, J. W.; Parsons, T. B.; Fairbanks, A. J. *ChemBioChem* **2008**, *9*, 2045–2051.
- (15) Huang, W.; Ochiai, H.; Zhang, X.; Wang, L. X. *Carbohydr. Res.* **2008**, *343*, 2903–2913.
- (16) (a) Huang, W.; Groothuys, S.; Heredia, A.; Kuijpers, B. H.; Rutjes, F. P.; van Delft, F. L.; Wang, L. X. *ChemBioChem* **2009**, *10*, 1234–1242. (b) Ochiai, H.; Huang, W.; Wang, L. X. *Carbohydr. Res.* **2009**, *344*, 592–598.

Scheme 2



(5) and have shown that it was a good substrate of the glycosynthase mutant EndoM-N175A for glycoprotein synthesis.¹³ Thus, the reaction of oxazoline (5) and acceptor (4) (donor/acceptor, 3:1) under the catalysis of EndoM-N175A gave the biotinylated *N*-glycan product (6) in 72% yield. The two terminal galactose residues were then selectively removed by treatment with β -1,4-galactosidase from *Bacteroides fragilis* to provide GlcNAc₂Man₃GlcNAc₂-LC-biotin (7), in which the two internal GlcNAc residues were exposed at the nonreducing terminus. Enzymatic extension of the sugar chain from the two GlcNAc residues would enable the synthesis of novel glycan structures. The advantage of introducing a biotin tag in the aglycon portion of the glycan primer (7) was apparent: it would facilitate the detection of the synthetic *N*-glycans bound in a glycan-binding protein microarray platform, or the biotinylated glycans could be directly immobilized on a streptavidin plate to provide a glycan array platform.

To test whether the two terminal β -1,2-linked GlcNAc residues of 7 are able to serve as acceptors for the next round of enzymatic transglycosylation, we first examined the Endo-A-catalyzed transglycosylation of 7 using Man₃GlcNAc oxazoline (8)¹⁰ as the donor substrate (Scheme 2). It was found that when oxazoline 8 and GlcNAc₂Man₃GlcNAc₂-LC-biotin (7) (donor/acceptor, 6:1) were incubated with Endo-A in a phosphate buffer at 30 °C, the transglycosylation reaction proceeded very efficiently, and after 2 h, almost all the starting material 7 was converted to the doubly glycosylated product 9 (as revealed by HPLC). The product was readily isolated by HPLC in 88% yield. MALDI-TOF MS analysis showed a single *m/z* species at 3055.12, which matches well with the theoretical data of 9 that carries three Man₃GlcNAc₂ cores (calculated, *M* =

3032.14; found *M* + Na = 3055.12). The newly formed glycosidic bonds in the Man₃GlcNAc₂ cores were assumed to be in the natural β -1,4-glycosidic linkage between the two GlcNAc residues on the basis of all previously reported stereospecificity of Endo-A-catalyzed transglycosylation.^{10,11,15} To further substantiate this assumption, compound 9 was treated with wild-type Endo-M that specifically hydrolyzes the β -1,4-glycosidic bond in natural *N*-glycan. It was found that treatment of 9 with Endo-M gave GlcNAc-LC-biotin (1 equiv), GlcNAc₂-Man₃GlcNAc (1 equiv) and Man₃GlcNAc (2 equiv) (data not shown), suggesting that the three Man₃GlcNAc₂ cores all have the natural GlcNAc- β -1,4-GlcNAc linkage in the core. The successful simultaneous enzymatic transfer of two Man₃GlcNAc moieties to the GlcNAc₂Man₃GlcNAc₂-LC-biotin indicates that the two terminal β -1,2-linked GlcNAc residues, albeit in a rigid and crowded environment on the *N*-glycan core, are accessible to Endo-A-catalyzed glycosylation.


Next, we examined the glycosylation of 7 by the glycosynthase mutant EndoM-N175A, using a large complex type glycan oxazoline (5) as the donor substrate. Interestingly, when a limited amount of oxazoline donor substrate was used, a selective glycosylation on the two terminal GlcNAc residues was observed. Thus, incubation of oxazoline 5 and acceptor 7 (donor/acceptor, 3:1) with EndoM-N175A at 30 °C for 4 h gave three products: the two monoglycosylated products (10a and 10b) and the doubly transglycosylated product 10c in 25, 5, and 8% yields, respectively (Scheme 2). The GlcNAc linked to the mannose on the α -1,6-arm was much more favorable for transglycosylation than the GlcNAc linked to the mannose at the α -1,3-arm, with a selectivity of 5:1 (25% vs 5%). Although both GlcNAc are β -1,2-linked to the mannose moiety, the

regioselectivity might result from the difference in steric hindrance, as the GlcNAc at the 6-arm would be spatially less hindered than the GlcNAc located on the α -1,3-arm. Nevertheless, double glycosylation could be achieved by further chemoenzymatic transglycosylation with excess amount of donor substrate for a longer incubation time. This was exemplified by further glycosylation of the purified monoglycosylated glycan **10a** and oxazoline **5** (3.5 mol equiv) under the catalysis of EndoM-N175A, giving the doubly glycosylated product (**10c**) in 50% yield. When Man₃GlcNAc oxazoline (**11**) was used as the donor substrate, an even higher regioselectivity in transglycosylation was observed. Incubation of **11** and **7** (3:1) with EndoA-N175A for 4 h gave 27% of **12a**, 3% of **12b**, and trace amount of the doubly glycosylated product (**12a:12b** = 9:1) (Scheme 2). The higher selectivity might be explained by the bulky structure of triantennary glycan (**11**) in comparison with the biantennary complex glycan **5**. It should be mentioned that the use of wild-type Endo-M for the reaction between acceptor **7** and the oxazoline **5** or **11** failed to provide the transglycosylation products due to the enzymatic hydrolysis of the acceptor **7** as well as the products that were formed (data not shown).


It should be mentioned that in the synthesis of large complex *N*-glycan clusters, most of the transglycosylation reactions were carried out on a relatively small scale. Nevertheless, the specific enzymatic transglycosylation usually gave a very clear HPLC profile, allowing easy quantification and isolation of the reaction products by HPLC. To characterize the transglycosylation products, the new compounds were purified by HPLC and were subjected to MALDI-TOF MS analysis, which confirmed that the products **10a** and **10b** were monotransglycosylated product and the **10c** was the doubly glycosylated product (see Experimental Section). To discriminate the two monotransglycosylated products **10a** and **10b**, specific enzymatic transformation coupled with MS analysis was applied (Figure S1, Supporting Information). Treatment of **10a** and **10b** with β -*N*-acetylglucosaminidase from *Xanthomonas manihotis* resulted in the removal of the remaining terminal GlcNAc, which exposed the α -1,3-Man residue in **10a** or the α -1,6-Man residue in **10b**. When the two intermediates, which had the same molecular mass, were then treated further with an α -1,2/ α -1,3-mannosidase from *X. manihotis*, only the exposed α -1,3-man residue in **10a** would be removed, leading to the formation of a species with a loss of 162 Da in molecular mass, while the α -1,6-Man residue exposed in **10b** would not be hydrolyzed. Thus, MALDI-TOF MS analysis of the resulting products led to an unambiguous assignment of **10a** and **10b** as the clusters with the additional glycan attached at the α -1,6-arm and the α -1,3-arm positions, respectively. Discrimination between **12a** and **12b** was achieved by similar enzymatic transformations of **12a** with β -*N*-acetylglucosaminidase and α -1,2/ α -1,3-mannosidase coupled with MS analysis (Figure S2, Supporting Information).

The regioselectivity observed in the EndoM-N175A-catalyzed transglycosylation also provided an opportunity to introduce distinct *N*-glycans at the α -1,6- and α -1,3-arms of the core, permitting the synthesis of novel hybrid *N*-glycan clusters. Thus, after the first selective transglycosylation of **7** with oxazoline (**5**) to produce compound **10a**, another distinct glycan, Man₃GlcNAc, was successfully introduced to the remaining terminal GlcNAc at the α -1,3-arm by Endo-A to give the hybrid *N*-glycan cluster **13** in essentially quantitative yield (Scheme 3). This result represents a remarkable example on the potential of the enzymatic transglycosylation for expanding the diversity of the glycan cluster structures.

Scheme 3



Scheme 4



Further Extension of the Sugar Chains in the Glycan Clusters by Tandem Enzymatic Transglycosylation. For those glycan clusters that contain terminal LacNAc moieties such as compounds **10a**, **10b**, **10c**, and **13**, further sugar chain extensions could be readily achieved by unmasking the terminal GlcNAc residues followed by repeat enzymatic transglycosylation. For example, treatment of **10c** with β -1,4-galactosidase from *B. fragilis* resulted in selective removal of the four terminal galactose residues to provide compound **14**, in which the four internal GlcNAc residues were exposed. Simultaneous glycosylation of these GlcNAc residues in **14** was achieved in a single step by its Endo-A-catalyzed transglycosylation with an excess amount of Man₃GlcNAc-oxazoline (**8**) (4 equiv per terminal GlcNAc) to give *N*-glycan cluster **15** in essentially quantitative yield (Scheme 4). The HPLC and MALDI-TOF MS profiles of the purified *N*-glycan cluster **15** were shown in Figure 1. The *m/z* species observed in the MS spectrum is in good agreement with the calculated molecular mass (observed, *m/z* = 6625.98; calculated, [M + Na] = 6625.41). Glycan cluster **15** consists of four terminal Man₃GlcNAc₂ cores and three internal




Figure 1. HPLC and MALDI-TOF MS profiles of *N*-glycan cluster 15.




Figure 2. A 45-lectin microarray platform for probing *N*-glycan clusters. (a) Lectin printing pattern; (b) fluorescent imaging of the lectin-recognition profiles of glycan clusters 9 and 15.

Man₃GlcNAc₂ cores. It would be worthwhile to emphasize that all the sugar residues in these enzymatically synthetic *N*-glycan clusters are connected to each other by the defined natural glycosidic bonds found in natural *N*-glycans, which usually demonstrate confined rotations of the chains than those linked through flexible spacers. Thus, the *N*-glycan clusters described in this work represent a new class of *N*-glycan clusters that are different from other synthetic oligosaccharide clusters in which mono- or oligosaccharides are linked with various spacers.

Lectin Array Characterization of the Synthetic *N*-Glycan Clusters. The availability of a class of structurally well-defined synthetic *N*-glycan clusters has now provided an opportunity to investigate how the unusual configuration of multiple *N*-glycan cores in a molecule would contribute to their recognition with various glycan-binding proteins such as lectins. For a preliminary study, a lectin microarray consisting of 45 lectins was used (Figure 2a), in which the lectins were immobilized on a glass slide as previously reported.¹⁷ All the biotinylated

N-glycan clusters were assayed at a concentration of 100 nM, and the bound glycans were detected by a fluorescence (Cy3)-labeled streptavidin. Figure 2b demonstrates a typical fluorescent imaging of the microarray profiles for glycan clusters 9 and 15. The lectin-binding profiles of all the synthetic *N*-glycan clusters are summarized in Figure 3. For each compound, its responses to the respective lectins were quantitatively determined and expressed as mean fluorescence intensity (MFI) of triplicate detections.

For the simple biotinylated *N*-glycans, 6 and 7, no apparent lectin interactions were observed under the screening conditions (at 100 nM glycan concentration) except for a weak binding of the GlcNAc-terminated glycan 7 to ConA, a lectin that is specific for terminal GlcNAc, Man, and Glc residues. The known sugar-binding specificity of the 45 lectins used in the present microarray analysis is listed in Figure S3 (Supporting Information). The cluster 9, which contains two terminal Man₃GlcNAc₂ cores, showed significant signals on spots for lectins Calsepa and ConA. These results are consistent with the known specificity of these two lectins, which recognize terminal mannose/GlcNAc residues and particularly high-mannose glycan.¹⁸ Glycans 10a and 10b picked up three lectins, Calsepa, ConA, and RCA120. RCA120 is a lectin specific for terminal β -Gal residues.¹⁹ The strong interactions between lectin Calsepa and 10a or 10b is an interesting observation. Calsepa is a mannose-binding-type Jacalin-related lectin (mJRL) with binding preference to small high-mannose *N*-glycan (Man₂₋₆). It is also reported that Calsepa interacts with sialo/asialo complex-type *N*-glycans with terminal Gal or GlcNAc. Interestingly bisecting GlcNAc dramatically enhances binding affinity of complex-type *N*-glycans with Calsepa.¹⁸ The strong interaction between Calsepa and 10a or 10b suggests that both the terminal Man₃GlcNAc core and the remaining terminal GlcNAc in 10a and 10b might bind to two distinct binding sites in the lectin simultaneously in a concerted manner, thus dramatically enhancing its affinity to the lectin. It should be noted that Calsepa did not show detectable affinity to the complex-type *N*-glycans 6 and 7 at 100 nM, despite the presence of terminal Gal and GlcNAc in the glycans.

The lectin microarray also revealed interesting properties for glycan cluster 10c, which bears four terminal Gal β 1-4GlcNAc moieties. First, it showed significantly enhanced affinity to the LacNAc-specific galectins RCA120 and ECA²⁰ as compared with the glycans 6, 10a, and 10b. The dramatic enhancement of affinity could be explained by the clustering effect of the Gal β 1-4GlcNAc ligands in 10c. Second, the Calsepa binding signals were also enhanced. More surprisingly, glycan cluster 10c also demonstrated significant affinity to ConA, although it does not contain terminal GlcNAc/Man residues. These results suggest that the appropriate clustering arrangement of the internal Man₃GlcNAc₂ cores in 10c may generate novel new binding sites or interfaces for lectin ConA that hitherto favors terminal mannose/GlcNAc residues. As to the Man₉GlcNAc₂-containing cluster 12a, it was recognized by 5 lectins in the microarray. In addition to its expected affinity to the high-mannose recognizing lectins, including Calsepa, ConA, and HHL, it also picked up two unexpected lectins, ABA and UDA.

(17) Kuno, A.; Uchiyama, N.; Koseki-Kuno, S.; Ebe, Y.; Takashima, S.; Yamada, M.; Hirabayashi, J. *Nat. Methods* 2005, 2, 851–856.

(18) Nakamura-Tsuruta, S.; Uchiyama, N.; Peumans, W. J.; Van Damme, E. J.; Totani, K.; Ito, Y.; Hirabayashi, J. *FEBS J.* 2008, 275, 1227–1239.

(19) Baenziger, J. U.; Fiete, D. *J. Biol. Chem.* 1979, 254, 9795–9799.

(20) De Boeck, H.; Loontjens, F. G.; Lis, H.; Sharon, N. *Arch. Biochem. Biophys.* 1984, 234, 297–304.



Lectin ABA has a known specificity for terminal Gal β 1–3GalNAc structure and a very weak affinity to the terminal GlcNAc residue on complex-type *N*-glycans (K_d at 100 μ M level).²¹ The reason why **12a** exhibits such a high affinity to lectin ABA is yet to be elucidated, but perhaps both the Man9 structure and the terminal GlcNAc at the other arm are involved in a simultaneous interaction with two binding sites in the lectin. The glycan clusters **10a** and **10b**, which contain a terminal GlcNAc but carry a complex glycan on the other arm, were not recognized by ABA. Lectin UDA (*Urtica dioica* agglutinin) is known to be specific for chitin oligomers (*N,N',N''*-triacyetylchitotriose and higher chitin oligosaccharides).^{22,23} The significant interaction between UDA and compound **12a** may suggest that the three internal GlcNAc residues may form a discontinuous glyco-epitope that would fit to the chitotriose-binding domain in the lectin.²³ Alternatively, the Man9GlcNAc2 moiety itself may also contribute directly to the binding, as compound **10a**, which contains a similar three internal GlcNAc motif but carries a complex *N*-glycan at the 6-arm, clearly did not bind to UDA. The glycan cluster **13**, which possesses both terminal Gal β 1–4GalNAc and high-mannose moieties, demonstrated the expected binding specificity for lectins Calpesa, ConA, and RCA120. But again, it also showed significant binding affinity

(24) (a) Hester, G.; Wright, C. S. *J. Mol. Biol.* **1996**, 262, 516–531. (b) Wright, C. S.; Hester, G. *Structure* **1996**, 4, 1339–1352.

(25) Kaku, H.; Van Damme, E. J.; Peumans, W. J.; Goldstein, I. J. *Arch. Biochem. Biophys.* **1990**, 279, 298–304.

- 17968 J. AM. CHEM. SOC. ■ VOL. 131, NO. 49, 2009

cluster **15** also picked up two chitin oligosaccharide-specific lectins, UDA²³ and LEL,²⁶ that recognize chitin oligosaccharides with three or more GlcNAc moieties. A plausible explanation is that the compact cluster of the multiple GlcNAc β 1–4GlcNAc moieties in **15** forms a novel discontinuous epitope that mimics the chitin oligosaccharide to provide a high-affinity structure to interact with the binding domain in the lectin. Notably, among the synthetic glycan clusters, only compound **15** showed significant binding to lectin LEL that is known to be specific for *N*-acetyl-chitooligosaccharide moieties (Figure 3). These experimental data suggest that the unusual configuration of the *N*-glycan cores in the defined *N*-glycan clusters creates novel lectin recognition motifs or glyco-epitopes that may implicate special roles of unusual *N*-glycans in a biological system. Recently, Dennis and co-workers have reported that the number and degree of branching (e.g., tetra-antennary vs biantennary) of complex type *N*-glycans in cell-surface receptors are critical factors to regulate cell proliferation and differentiation, due to the distinct affinities of the differentially branched *N*-glycans to galectins.²⁷ On the other hand, the highly branched and compactly packed *N*-glycan clusters described in this work, which show unusually high affinity to some specific lectins, may be used as specific inhibitors to decipher the functional roles of *N*-glycans and lectins in a given biological process.

Conclusion

A facile synthesis of a class of novel *N*-glycan clusters was achieved via tandem chemoenzymatic transglycosylation. The unusual configurations and highly branched packing of the subunit *N*-glycans in the clusters create new structural motifs, demonstrating novel carbohydrate-lectin recognition patterns. These synthetic *N*-glycan clusters should be valuable for functional glycomics studies to unveil new functions for both glycans and carbohydrate-binding proteins.

Experimental Section

Materials and Methods. 1- β -Azido-GlcNAc (**1**) was prepared by the reported method.²⁸ Succinimidyl-6-(biotinamido)hexanoate (NHS-LC-biotin, **3**) was purchased from Pierce Biotechnology, Inc. CT-GlcNAc oxazoline (**5**),¹³ Man₃GlcNAc oxazoline,¹⁰ and Man₉GlcNAc oxazoline¹² were synthesized following our previously reported procedures. The β -1,4-galactosidase, β -*N*-acetylglucosaminidase, and α -1,2/1,3-mannosidase were purchased from New England Biolabs, Inc. Endo-A was overproduced, following the literature.²⁹ EndoM-N175A was overproduced according to the previously reported method.¹² The activity unit of Endo-A was defined as the following: 1 unit of Endo-A is the amount of enzyme required to hydrolyze 1 μ mol Man₉GlcNAc₂Asn (substrate concentration, 10 mM) in one minute at 30 °C in a phosphate buffer (50 mM, pH 6.5). The unit of glycosynthase activity of EndoM-N175A was defined as the following: 1 unit of EndoM-N175A is the amount of enzyme required to transfer 1 μ mol Man₉GlcNAc oxazoline to GlcNAc-pNP at 1:2 donor/acceptor ratio in one minute. All the other reagents were purchased from Sigma/Aldrich and used as received.

Analytical RP-HPLC was performed on a Waters 626 HPLC instrument with a Symmetry300 C18 column (5.0 μ m, 4.6 mm $\times$

250 mm) at 40 °C. The column was eluted at a flow rate of 1.0 mL/min using a linear gradient of 0–90% MeCN containing 0.1% trifluoroacetic acid (TFA) for 30 min. The yields were calculated on the basis of the HPLC quantification of both starting materials and products [absorbance (abs) at 214 nm], using the following formula: yield (%) = [product abs/(starting material Abs + product abs)] $\times$ 100. Preparative HPLC was performed on a Waters 600 HPLC instrument with a preparative C18 column (Symmetry300, 7.0 μ m, 19 mm $\times$ 300 mm). The column was eluted with a suitable gradient of water/acetonitrile containing 0.1% TFA. NMR spectra were measured with JEOL ECX 400 MHz and/or Inova 500 MHz NMR spectrometers. All chemical shifts were assigned in ppm. The ESI-MS spectra were measured on a Waters Micromass ZQ-4000 single quadrupole mass spectrometer. MALDI-TOF MS measurement was performed on an Autoflex II MALDI-TOF mass spectrometer (Bruker Daltonics). The instrument was calibrated by using ProteoMass Peptide MALDI-MS calibration kit (MSCAL2, Sigma/Aldrich). The matrix used for glycans is 2,5-dihydroxybenzoic acid (DHB) (10.0 mg/mL in 50% acetonitrile containing 0.1% trifluoroacetic acid). The measuring conditions in detail: 337 nm nitrogen laser with 100 μ J output; laser frequency 50.0 Hz; laser power 30–45%; linear mode; positive polarity; detection range 1000–10000; pulsed ion extraction: 70 ns; high voltage: on; realtime smooth: high; shots: 500–2000.

Synthesis of 1-(6-Biotinamido)hexanoylamino-1-deoxy-2-acetamido-2-deoxy- β -D-glucopyranose (4). 1- β -Azido-GlcNAc (**1**) (10 mg, 38 μ mol) was dissolved in MeOH (1.0 mL) containing 5% palladium on carbon (5.0 mg). The mixture was hydrogenated at r.t. under atmospheric pressure overnight. The residue was filtered via a Celite pad, and the filtrate was concentrated. The obtained crude syrup of 1- β -amino-GlcNAc (**2**) was directly used without additional purification. A solution of the crude compound **2** and NHS-LC-biotin (**3**) (20 mg, 44 μ mol) in a mixed solvent of phosphate buffer (50 mM, pH 7.5, 1.0 mL), MeCN (1.0 mL) and DMSO (1.0 mL) was shaken at r.t. overnight. The residue was subject to preparative HPLC for purification. The fractions containing product were combined and lyophilized to give GlcNAc-LC-biotin (**4**) as white powder (17 mg, 79% for two steps). ¹H NMR (D₂O, 400 MHz): δ 4.93 (d, 1H, *J* = 9.6 Hz, H-1 of GlcNAc), 4.47 (dd, 1H, *J* = 4.8, 8.0 Hz, H-7 of biotin), 4.29 (dd, 1H, *J* = 4.4, 8.0 Hz, H-8 of biotin), 3.74 (dd, 1H, *J* = 2.0, 12.4 Hz, H-6a of GlcNAc), 3.67 (t, 1H, *J* = 10.0 Hz, H-2 of GlcNAc), 3.61 (dd, 1H, *J* = 4.6, 12.4 Hz, H-6b of GlcNAc), 3.47 (t, 1H, *J* = 10.0 Hz, H-3 of GlcNAc), 3.38 (m, 2H, H-4 and H-5 of GlcNAc), 3.21 (m, 1H, H-4 of biotin), 3.03 (t, 2H, *J* = 6.8 Hz, CH₂NHCO), 2.87 (dd, 1H, *J* = 4.8, 13.0 Hz, H-6a of biotin), 2.63 (d, 1H, *J* = 13.0 Hz, H-6b of biotin), 2.14 (m, 4H, CH₂CONH), 1.86 (s, 3H, Ac of GlcNAc), 1.61–1.34 (m, 8H, CH₂), 1.26 (m, 2H, CH₂), 1.16 (m, 2H, CH₂); ¹³C NMR (D₂O, 100 MHz): δ 177.7, 176.6, 174.5, 165.3, 78.3, 77.6, 74.1, 71.2, 69.4, 62.1, 60.5, 60.2, 55.4, 54.3, 39.7, 39.0, 35.7, 35.5, 28.0, 27.8, 27.7, 25.5, 25.2, 25.0, 22.0; analytical HPLC: *t*_R = 12.2 min; ESI-MS: calculated for C₂₄H₄₁N₅O₈S, *M* = 559.27 Da; found, 560.67 [*M* + H]⁺.

Synthesis of Biotinylated Complex Type *N*-Glycan (6). A solution of GlcNAc-LC-biotin (**4**) (1.0 mg, 1.8 μ mol) and CT-GlcNAc oxazoline (**5**) (7.5 mg, 5.3 μ mol) in a phosphate buffer (50 mM, pH 7.5, 100 μ L) was incubated with EndoM-N175A (125 mU) at 30 °C for 8 h. The residue was subject to preparative HPLC for purification. The fractions containing product were combined and lyophilized to give CT-GlcNAc₂-LC-biotin (**6**) as white powder (2.5 mg, 72%). ¹H NMR (D₂O, 400 MHz): δ 4.97 (s, 1H, H-1 of Man⁴), 4.92 (d, 1H, *J* = 9.6 Hz, H-1 of GlcNAc¹), 4.78 (s, 1H, H-1 of Man⁴), 4.62 (s, 1H, H-1 of Man³), 4.46 (m, 4H, H-1 of GlcNAc², H-1 of GlcNAc⁵, H-1 of GlcNAc^{5'}, H-7 of biotin), 4.33 (dd, 2H, *J* = 2.4, 7.8 Hz, H-1 of Gal⁶ and Gal^{6'}), 4.28 (dd, 1H, *J* = 4.6, 7.8 Hz, H-8 of biotin), 4.11 (m, 1H), 4.06 (m, 1H), 3.97 (m, 1H), 3.19 (quintet, 1H, *J* = 4.8 Hz, H-4 of biotin), 3.03 (t, 2H, *J* = 6.8 Hz, CH₂NHCO), 2.86 (dd, 1H, *J* = 4.8, 12.8 Hz, H-6a of biotin), 2.65 (d, 1H, *J* = 12.8 Hz, H-6b of biotin), 2.12 (m, 4H,

(26) Kilpatrick, D. C. *Biochem. J.* **1980**, *185*, 269–272.

(27) Lau, K. S.; Partridge, E. A.; Grigorian, A.; Silvescu, C. I.; Reinhold, V. N.; Demetriou, M.; Dennis, J. W. *Cell* **2007**, *129*, 123–134.

(28) O'Reilly, M. K.; Collins, B. E.; Han, S.; Liao, L.; Rillahan, C.; Kitov, P. I.; Bundle, D. R.; Paulson, J. C. *J. Am. Chem. Soc.* **2008**, *130*, 7736–7745.

(29) Fujita, K.; Tanaka, N.; Sano, M.; Kato, I.; Asada, Y.; Takegawa, K. *Biochem. Biophys. Res. Commun.* **2000**, *267*, 134–138.

CH_2CONH), 1.94 (s, 3H, Ac), 1.91 (s, 3H, Ac), 1.90 (s, 3H, Ac), 1.85 (s, 3H, Ac), 1.61–1.34 (m, 8H, CH_2), 1.28 (m, 2H, CH_2), 1.16 (m, 2H, CH_2); ^{13}C NMR (D_2O , 100 MHz) δ 177.7, 176.6, 174.7, 174.6, 174.5, 165.3 (7 $\times$ CO), 102.9 (C-1 of Gal⁶ and Gal^{6'}), 101.5 (C-1 of GlcNAc²), 100.4 (C-1 of Man³), 99.7 (C-1 of Man⁴), 99.6 (C-1 of GlcNAc⁵ and GlcNAc^{5'}), 97.0 (C-1 of Man^{4'}), 78.6 (C-1 of GlcNAc¹), 62.8 (C-8 of biotin), 60.5 (C-7 of biotin), 55.8 (C-4 of biotin), 39.7 (C-6 of biotin), 39.0 (2 $\times$ CH_2NHCO), 35.7, 35.5 (2 $\times$ CH_2CONH), 27.9, 27.8, 27.6, 25.4, 25.2, 24.8 (6 $\times$ CH_2), 22.3, 22.2, 22.0 (4 $\times$ Ac); analytical HPLC: t_R = 11.2 min; MALDI-TOF-MS: calculated for $\text{C}_{78}\text{H}_{130}\text{N}_8\text{O}_{48}\text{S}$, M = 1978.77 Da; found, 2002.68 [M + Na]⁺.

Synthesis of the Biotinylated Complex Type N-Glycan (7).

A solution of CT-GlcNAc₂-LC-biotin (**6**) (2.5 mg, 1.3 μmol) in a phosphate buffer (50 mM, pH 5.5, 300 μL) was incubated with β -1,4-galactosidase (100 U) from *Bacteroides fragilis* (New England Biolabs) at 37 °C for 24 h. The reaction was monitored by analytical HPLC until complete removal of terminal galactose. The residue was subject to preparative HPLC. The fractions containing product were combined and lyophilized to give GlcNAc₂Man₃GlcNAc₂-LC-biotin (**7**) as white powder (2.1 mg, quantitative yield). ^1H NMR (D_2O , 400 MHz): δ 4.98 (s, 1H, H-1 of Man⁴), 4.93 (d, 1H, J = 9.6 Hz, H-1 of GlcNAc¹), 4.78 (s, 1H, H-1 of Man^{4'}), 4.64 (s, 1H, H-1 of Man³), 4.48 (m, 2H, H-1 of GlcNAc², H-7 of biotin), 4.43 (d, 2H, J = 8.6 Hz, H-1 of GlcNAc⁵ and GlcNAc^{5'}), 4.29 (dd, 1H, J = 4.4, 8.0 Hz, H-8 of biotin), 4.12 (m, 1H), 4.05 (m, 1H), 3.97 (m, 1H), 3.20 (quintet, 1H, J = 4.8 Hz, H-4 of biotin), 3.03 (t, 2H, J = 6.8 Hz, CH_2NHCO), 2.87 (dd, 1H, J = 4.8, 13.2 Hz, H-6a of biotin), 2.63 (d, 1H, J = 12.8 Hz, H-6b of biotin), 2.13 (m, 4H, CH_2CONH), 1.94 (s, 3H, Ac), 1.91 (s, 6H, 2 $\times$ Ac), 1.86 (s, 3H, Ac), 1.62–1.34 (m, 8H, CH_2), 1.27 (m, 2H, CH_2), 1.15 (m, 2H, CH_2); ^{13}C NMR (D_2O , 100 MHz) δ 177.7, 176.6, 174.7, 174.6, 174.5, 165.3 (7 $\times$ CO), 101.3 (C-1 of GlcNAc²), 100.4 (C-1 of Man³), 99.6 (C-1 of Man⁴, C-1 of GlcNAc⁵ and GlcNAc^{5'}), 97.0 (C-1 of Man^{4'}), 80.4, 79.5, 78.6 (C-1 of GlcNAc¹), 78.2, 76.4, 76.2, 75.8, 74.4, 74.3, 73.5, 73.3, 73.2, 72.8, 72.7, 72.0, 70.2, 69.9, 69.5, 69.4, 67.3, 65.8, 65.7, 62.1 (C-8 of biotin), 61.7, 61.6, 60.6 (C-7 of biotin), 60.2, 59.8, 55.4, 55.3 (C-4 of biotin), 39.7 (C-6 of biotin), 39.0 (2 $\times$ CH_2NHCO), 35.7, 35.5 (2 $\times$ CH_2CONH), 27.9, 27.8, 27.6, 25.4, 25.2, 24.8 (6 $\times$ CH_2), 22.3, 22.2, 22.0 (4 $\times$ Ac); analytical HPLC: t_R = 11.4 min; MALDI-TOF-MS: calculated for $\text{C}_{66}\text{H}_{110}\text{N}_8\text{O}_{38}\text{S}$, M = 1654.66 Da; found, 1678.07 [M + Na]⁺.

Synthesis of the N-Glycan Cluster (9). A solution of GlcNAc₂Man₃GlcNAc₂-LC-biotin (**7**) (0.20 mg, 0.12 μmol) and Man₃GlcNAc oxazoline (**5**) (0.50 mg, 0.72 μmol) in phosphate buffer (50 mM, pH 7.5, 15 μL) was incubated with Endo-A (2.0 mU) at 30 °C for 1 h. The reaction was monitored by analytical HPLC until the completion of the reaction. The residue was subject to preparative HPLC purification. The fractions containing product were combined and lyophilized to give Man₃GlcNAc₂Man(1,6)-[Man₃GlcNAc₂Man(1,3)]-ManGlcNAc₂-LC-biotin (**9**) as a white powder (88% yield). Analytical HPLC: t_R = 11.1 min; MALDI-TOF-MS: calculated for $\text{C}_{118}\text{H}_{196}\text{N}_{10}\text{O}_{78}\text{S}$, M = 3033.14 Da, found, 3055.12 [M + Na]⁺.

Transglycosylation of Glycan 7 with the Complex Type Glycan Oxazoline 5. Synthesis of Glycan Clusters 10a and 10b. A solution of GlcNAc₂Man₃GlcNAc₂-LC-biotin (**7**) (0.50 mg, 0.30 μmol) and CT-GlcNAc oxazoline (**5**) (1.3 mg, 0.91 μmol) in a phosphate buffer (50 mM, pH 7.5, 20 μL) was incubated with EndoM-N175A (30 mU) at 30 °C. The reaction was monitored by analytical HPLC. After 4 h, HPLC showed the formation of three new products, which were readily purified by HPLC to give the 6-arm glycosylated product CT-GlcNAc₂Man(1,6)-[GlcNAcMan(1,3)]-LC-biotin (**10a**) in 25% yield; the 3-arm glycosylated product CT-GlcNAc₂Man(1,3)-[GlcNAcMan(1,6)]-LC-biotin (**10b**) in 5% yield, and the doubly glycosylated product **10c** in 8% yield.

CT-GlcNAc₂Man(1,6)-[GlcNAcMan(1,3)]-ManGlcNAc₂-LC-biotin (10a): white powder, analytical HPLC: t_R = 10.8 min; MALDI-TOF-MS: calculated for $\text{C}_{120}\text{H}_{199}\text{N}_{11}\text{O}_{78}\text{S}$, M = 3074.17 Da; found, 3097.78 [M + Na]⁺.

CT-GlcNAc₂Man(1,3)-[GlcNAcMan(1,6)]-ManGlcNAc₂-LC-biotin (10b): white powder, analytical HPLC: t_R = 11.1 min; MALDI-TOF-MS: calculated for $\text{C}_{120}\text{H}_{199}\text{N}_{11}\text{O}_{78}\text{S}$, M = 3074.17 Da; found, 3098.36 [M + Na]⁺.

CT-GlcNAc₂Man(1,6)-[CT-GlcNAc₂Man(1,3)]-ManGlcNAc₂-LC-biotin (10c): white powder, analytical HPLC: t_R = 10.2 min; MALDI-TOF-MS: calculated for $\text{C}_{174}\text{H}_{288}\text{N}_{14}\text{O}_{118}\text{S}$, M = 4496.24 Da; found, 4519.69 [M + Na]⁺.

Synthesis of N-Glycan Cluster 10c from the Monotransglycosylated Compound 10a. A solution of **10a** (0.30 mg, 0.10 μmol) and CT-GlcNAc oxazoline (**5**) (0.50 mg, 0.35 μmol) in a phosphate buffer (50 mM, pH 7.5, 5.0 μL) was incubated with EndoM-N175A (30 mU) at 30 °C for 8 h. The reaction mixture was subject to HPLC purification to give the doubly glycosylated product **10c** (50% yield).

Transglycosylation with the Man₉GlcNAc Oxazoline (11) by EndoM-N175A. A solution of GlcNAc₂Man₃GlcNAc₂-LC-biotin (**7**) (0.20 mg, 0.12 μmol) and Man₉GlcNAc oxazoline (**11**) (0.60 mg, 0.36 μmol) in a phosphate buffer (50 mM, pH 7.5, 15 μL) was incubated with EndoM-N175A (10 mU) at 30 °C. The reaction was monitored by analytical HPLC. After 4 h, HPLC indicated the formation of the 6-arm glycosylated product **12a** in 27% yield and the 3-arm glycosylated product **12b** in 3% yield. The products were purified by HPLC. The doubly glycosylated product was formed in only trace amount (as indicated by MS analysis), which was not isolated for further analysis.

Man₉GlcNAc₂Man(1,6)-[GlcNAcMan(1,3)]-ManGlcNAc₂-LC-biotin (12a): white powder, analytical HPLC: t_R = 10.7 min; MALDI-TOF-MS: calculated for $\text{C}_{128}\text{H}_{213}\text{N}_9\text{O}_{88}\text{S}$, M = 3318.13 Da; found, 3341.78 [M + Na]⁺.

Man₉GlcNAc₂Man(1,3)-[GlcNAcMan(1,3)]-ManGlcNAc₂-LC-biotin (12b): white powder, analytical HPLC: t_R = 11.0 min; MALDI-TOF-MS: calculated for $\text{C}_{128}\text{H}_{213}\text{N}_9\text{O}_{88}\text{S}$, M = 3318.13 Da; found, 3341.57 [M + Na]⁺.

Synthesis of N-Glycan Cluster 13. A solution of **10a** (0.10 mg, 33 nmol) and Man₃GlcNAc oxazoline (**5**) (0.10 mg, 0.14 μmol) in a phosphate buffer (50 mM, pH 7.5, 5.0 μL) was incubated with Endo-A (1.0 mU) at 30 °C for 2 h. Analytical HPLC monitoring indicated the formation of the hybrid glycosylated product **13** in a quantitative yield. The product was purified by HPLC to give CT-GlcNAc₂Man(1,6)-[Man₃GlcNAc₂Man(1,3)]-ManGlcNAc₂-LC-biotin (**13**). Analytical HPLC: t_R = 10.4 min; MALDI-TOF-MS: calculated for $\text{C}_{146}\text{H}_{242}\text{N}_{12}\text{O}_{98}\text{S}$, M = 3763.40 Da; found, 3786.87 [M + Na]⁺.

Synthesis of N-Glycan Cluster 14. A solution of **10c** (0.15 mg, 33 nmol) in a phosphate buffer (50 mM, pH 5.5, 30 μL) was incubated with β -1,4-galactosidase (10 U) at 37 °C for overnight. The reaction was monitored by analytical HPLC until the complete removal of all the terminal galactose moieties. The residue was subject to preparative HPLC purification. The fractions containing product were combined and lyophilized to give GlcNAc₂Man₃-GlcNAc₂Man(1,6)-[GlcNAc₂Man₃GlcNAc₂Man(1,3)]-ManGlcNAc₂-LC-biotin (**14**) (quantitative yield) as a white powder. Analytical HPLC: t_R = 10.7 min; MALDI-TOF-MS: calculated for $\text{C}_{150}\text{H}_{248}\text{N}_{14}\text{O}_{98}\text{S}$, M = 3847.67 Da; found, 3870.97 [M + Na]⁺.

Synthesis of N-Glycan Cluster 15. A solution of **14** (0.10 mg, 26 nmol) and Man₃GlcNAc oxazoline (**5**) (0.30 mg, 0.44 μmol) in a phosphate buffer (50 mM, pH 7.5, 15 μL) was incubated with Endo-A (2.0 mU) at 30 °C. HPLC monitoring indicated the complete transglycosylation after 2 h incubation. The reaction mixture was subject to preparative HPLC. The fractions containing product were combined and lyophilized to give the N-glycan cluster (**15**) (quantitative yield). Analytical HPLC: t_R = 9.6 min; MALDI-

TOF-MS: calculated for $C_{254}H_{420}N_{18}O_{178}S$, $M = 6602.41$ Da; found, 6625.98 $[M + Na]^+$.

Lectin Microarray Analysis. Lectins were immobilized on glass slides according to the previously reported method.¹⁷ The lectin microarray profilings of the glycan clusters were carried out following the literature method,¹⁷ with some modifications. Briefly, the biotinylated *N*-glycan clusters were applied on lectin arrays at a concentration of 100 nM and incubated at 4 °C for 5 h. After washing to remove the unbound *N*-glycans, the lectin arrays were incubated with a fluorescence (Cy3)-labeled streptavidin at a concentration of 1 μ g/mL at r.t. for 30 min. The array-captured *N*-glycans were then visualized and quantified by scanning the arrays with a specialized GlycoStation (GP Biosciences Ltd., Yokohama, Japan). For each compound, the binding responses with the lectin arrays were quantitatively determined and expressed as mean fluorescence intensity (MFI) of triplicate detections. In all the assays, GlcNAc-LC-biotin (**4**) was used as the control. Overlay

plots were produced using JMP-Genomics 4.0 software package (SAS Institute in Cary, North Carolina).

Acknowledgment. We thank Prof. Kaoru Takegawa for providing the pGEX-2T/Endo-A plasmid, Prof. Kenji Yamamoto and Ms. Midori Umekawa for providing the pET23b-Endo-M plasmid, and Dr. Cishan Li for expressing the endoenzymes. This work was supported by the National Institutes of Health (NIH) Grants R01 GM080374 (to L.X.W.) and U01 CA128416 (to D.W.).

Supporting Information Available: Complete ref 4a; the enzymatic transformation coupled with MS analysis for the characterization of the regioselective transglycosylation products **10a**, **10b**, and **12a**; the ¹H NMR, ¹³C NMR, MS spectra, and HPLC profiles of key compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JA9078539